Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun;4(2):145-57.
doi: 10.1007/s40121-015-0070-1. Epub 2015 Jun 2.

Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use

Andrew Ustianowski  1 , Joop E Arends
Affiliations

Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use

Andrew Ustianowski et al. Infect Dis Ther. 2015 Jun.

Abstract

Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies-informing on its efficacy, use, and adverse features-and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008-focusing on efficacy, side effects, and utility.

PubMed Disclaimer

References

    1. Pozniak A. Tenofovir: what have over 1 million years of patient experience taught us? Int J Clin Pract. 2008;62:1285–1293. doi: 10.1111/j.1742-1241.2008.01817.x. - DOI - PubMed
    1. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312:410–425. doi: 10.1001/jama.2014.8722. - DOI - PubMed
    1. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361:2230–2240. doi: 10.1056/NEJMoa0906768. - DOI - PMC - PubMed
    1. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204:1191–1201. doi: 10.1093/infdis/jir505. - DOI - PMC - PubMed
    1. Moyle GJ, Stellbrink HJ, Compston J, et al. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther. 2013;18:905–913. doi: 10.3851/IMP2667. - DOI - PubMed

LinkOut - more resources